Nolvadex (Tamoxifen Citrate)

Nolvadex (tamoxifen citrate) acts on estrogen‑dependent pathways in breast tissue and is indicated for several oncologic indications.

• Estrogen receptor‑positive breast cancer: treatment of invasive disease in women and men.
• Adjuvant therapy for breast cancer: reduction of recurrence risk after surgery, radiation or chemotherapy.
• High‑risk women: risk reduction to prevent development of breast cancer in women with a strong family or genetic predisposition.

• Tamoxifen citrate binds competitively to estrogen receptors in breast tissue, acting as an antagonist that blocks estrogen‑mediated transcription. By preventing estrogen from stimulating cellular proliferation, it induces apoptosis and inhibits growth of hormone‑dependent tumor cells. In other tissues it may exhibit partial agonist activity, but its primary antineoplastic effect derives from estrogen receptor blockade in the breast.

Nolvadex may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hot flashes: transient feeling of warmth and sweating.
• Nausea: mild to moderate upset stomach.
• Fatigue: generalized tiredness.
• Vaginal discharge or dryness: changes in vaginal secretions.

Serious or Rare Side Effects

• Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs.
• Endometrial cancer: abnormal growth of the uterine lining.
• Severe liver injury: jaundice, elevated enzymes, hepatic failure.

Before initiating Nolvadex, clinicians should evaluate several safety considerations.

• Assess thromboembolic risk: review history of clotting disorders or recent surgery.
• Monitor hepatic function: perform baseline liver enzymes and periodic testing.
• Evaluate uterine health: consider endometrial surveillance in post‑menopausal patients.
• Counsel on pregnancy potential: avoid use in pregnant or nursing women unless benefits outweigh risks.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Tamoxifen citrate interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): reduce conversion to active metabolites, decreasing effectiveness.
• Anticoagulants (e.g., warfarin): may increase bleeding risk; close INR monitoring required.

Moderate Interactions (Monitor Closely)

• Hormonal contraceptives: may reduce contraceptive efficacy.
• SSRIs with weak CYP2D6 inhibition (e.g., sertraline): possible modest effect on tamoxifen metabolism.
• Aromatase inhibitors: concurrent use generally not recommended due to overlapping endocrine effects.